Stockreport

Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control

Protagonist Therapeutics, Inc.  (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com